Stocklytics Platform
Asset logo for symbol TRDA
Entrada Therapeutics
TRDA58
$10.81arrow_drop_up0.92%$0.09
Asset logo for symbol TRDA
TRDA58

$10.81

arrow_drop_up0.92%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Entrada Therapeutics (TRDA) Stocklytics Forecast

The stock price prediction for Entrada Therapeutics, Inc. (TRDA) is a topic of interest for investors. Many financial analysts and experts have made forecasts and predictions about the future performance of TRDA stock. While it is important to note that these predictions are not guaranteed to be accurate, they can provide some insights and perspectives on the potential trajectory of the stock.
According to some analysts, the stock price of Entrada Therapeutics, Inc. is expected to experience growth in the coming years. They believe that the company's focus on developing innovative therapeutics and its strong pipeline of potential drugs could drive positive investor sentiment and contribute to an increase in the stock price. Additionally, the market potential for Entrada's targeted drugs for various diseases and conditions could attract attention from investors.
add Entrada Therapeutics to watchlist

Keep an eye on Entrada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Entrada Therapeutics (TRDA) stock?

Analysts have set a target price of $20.73 for Entrada Therapeutics (TRDA), based on forecasts from 11 analysts. The predicted price range extends from a high of $25 to a low of $10. This represents a potential increase of up to 131.27% and a decrease of -7.49% from the current price of $10.81. These forecasts are as of 2021 Nov 23.
help

What are the analyst ratings for Entrada Therapeutics (TRDA) stock?

Currently, there are no analyst ratings available for Entrada Therapeutics (TRDA), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Entrada Therapeutics (TRDA) stock?

At present, there is no AI or machine-learning-based price prediction available for Entrada Therapeutics (TRDA) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level